Ribavirin for the Treatment of SARS-CoV-2
As a contract research organization, Creative Biolabs is dedicated to discovering and developing drugs for viral diseases and other emerging infectious diseases. Our abundant experience, extensive expertise and advanced infrastructure enable us to provide unmatched services with unparalleled quality to help our customers optimize their development plans and accelerate the progress of new drug development.
Wuhan coronavirus infection is an emerging disease that was first reported in China and has now spread to many countries. The disease is an acute respiratory disease caused by the 2019 new coronavirus (SARS-CoV-2) named by the International Committee on Taxonomy of Viruses (ICTV). SARS-CoV-2, belonging to the Coronaviridae family, is a positive-sense, single-stranded RNA coronavirus. Like two other severe acute respiratory syndrome coronaviruses (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 is also classified as a beta genus coronavirus. Since the outbreak, SARS-CoV-2 has caused thousands of infections and hundreds of deaths. Currently, there is no specific treatment against the new virus. Therefore, identifying effective antiviral agents to combat the disease is urgently needed.
One of the fastest and most effective methods of drug discovery is to test whether existing antiviral drugs can effectively treat emerging virus infections. Researchers are evaluating countermeasures for SARS-CoV-2 using SARS and MERS as prototypes. Several antiviral drugs including ribavirin, interferons and the anti-HIV combination lopinavir/ritonavir or remdesivir have shown promise against MERS in animal models and are being assessed versus SARS-CoV-2.
Ribavirin is a guanosine analog with broad-spectrum antiviral activity and has been used to treat severe respiratory syncytial virus infection, HCV infection and viral hemorrhagic fevers. Its exact mechanism of action is unclear, but inhibition of mRNA capping and induction of mutations in RNA-dependent viral replication have been considered as a possible antiviral mechanism for RNA viruses. Although ribavirin has been treating the coronavirus family for a long time, its efficacy and safety for SARS-CoV-2 need to be further validated and evaluated.
Creative Biolabs’s employees work together to assist you in the discovery, development, and production of new drugs against SARS-CoV-2. We provide a full range of standard assays to evaluate the antiviral efficiency of ribavirin, including measuring the effects of ribavirin on the cytotoxicity, virus yield and infection rates of SARS-CoV-2s.
In addition to testing existing drugs, we are also committed to the development of new drugs for the treatment of SARS-CoV-2 infections, including:
Our mission is to be a responsible and reliable drug discovery contract research partner throughout your project. Our drug discovery services for SARS-CoV-2 are designed to reduce your costs and timelines, helping you meet your drug discovery milestones. If you have any questions about our services, please contact us with our technical team to discuss how we can help with your drug discovery project.For Research Use Only. We do not provide direct services or products for patients.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.